investor_presentation
Zendesk
Loading viewer...
investor_presentation
Format: PDF investor_presentation
Halozyme is a profitable biopharma company focused on its proprietary ENHANZE® drug delivery platform combined with autoinjector device technology. The company projects 2022 revenue of $655-685 million, representing 48-55% growth, driven by diverse revenue streams including partner collaborations and commercialized products.
investor_presentation
18 Pages
investor_presentation
55 Pages
Zenion Laboratories
BEM Bangkok Expressway Metro 2023 Investor Presentation
investor_presentationinvestor_presentation
24 Pages
Bangkok Expressway and Metro Public Company
investor_presentation
Zendesk